Maha Eltemamy is a pharmacist and patient safety advocate with nearly two decades of experience across the pharmaceutical industry in CETRIS, Middle East and Africa. Throughout her career, she has remained driven by a single purpose: strengthening trust in medicines by ensuring that patient safety remains at the center of healthcare systems.

Maha joined Roche in 2008. Starting in commercial roles, she gained a unique perspective on the real-world challenges patients and healthcare providers face when accessing and using medicines. This early exposure shaped her belief that the true value of innovation lies not only in discovery, but also in the responsible monitoring of medicines once they reach patients. In 2011, Maha transitioned into pharmacovigilance, dedicating her career to advancing drug safety systems and strengthening collaboration between industry, healthcare professionals, and regulators. Over the years, she has played a key role in developing regional pharmacovigilance
capabilities across diverse healthcare landscapes, supporting the evolution of safety systems in both emerging and mature markets.

Today, Maha leads a Regional Pharmacovigilance Hub responsible for safety oversight. In this role, she champions a forward-looking vision for pharmacovigilance – one that moves beyond compliance to embrace innovation, data-driven insights, and stronger partnerships to better detect, understand, and manage medicine-related risks.

Maha is particularly passionate about empowering teams and fostering a culture where patient safety is a shared responsibility. She actively advocates for greater transparency and accessibility of safety information, believing that patients and caregivers should be equipped with the knowledge that supports confident and informed treatment decisions. Through her leadership and advocacy, Maha continues to contribute to the transformation of pharmacovigilance into a more connected, proactive, and patient-centered discipline – one that ultimately strengthens public trust and improves outcomes for patients worldwide.